Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endo Pharmaceuticals names new board member
Mr Montague, who was CEO and a director of Mark IV Industries, retired in July 2009. Mark IV is a diversified global manufacturer of highly-engineered systems and components
Mr Montague, who was CEO and a director of Mark IV Industries, retired in July 2009. Mark IV is a diversified global manufacturer of highly-engineered systems and components
According to the company, the Quill SRS Polydioxanone (PDO) is a longer-lasting absorbable suture, which is typically used for deeper tissue closures while Quill SRS Monoderm is made
This study is designed to evaluate the safety, tolerability and clinical activity of topically applied ESBA105 in uveitis patients. ESBA105 is a single-chain antibody fragment directed against TNF-alpha,
Prior to Accumetrics, Mr Tibbitts served as CFO of CryoCor, a medical device company. Before joining CryoCor, Mr Tibbitts served as CFO of Elitra Pharmaceuticals, a biotechnology company,
According to the company, the Hemopurifier is a medical device that assists the immune response in combating infectious disease through real-time therapeutic filtration of infectious viruses and immunosuppressive
Under the agreement, ParkwayHealth will become the Asian affiliate in The Global Prevention Network, a select group of healthcare institutions with recognized preventive and executive health programs. US
The Phase IIa trial is a multicenter, randomized, double-blind, placebo-controlled study primarily investigating the safety and tolerability of EHT 0202 in approximately 150 patients with Alzheimer’s disease. The
If approved, Arzerra (ofatumumab) would be indicated for the treatment of patients with chronic lymphocytic leukemia who have previously failed, or are inappropriate for, standard therapies. The marketing
Hawaii Biotech is developing a West Nile recombinant sub-unit vaccine to induce protective immunity in recipients of the vaccine. The results demonstrated a favorable safety profile in 24
Clarus Ventures led the syndicate, which includes the founding investor, MVM Life Science Partners, and the Novartis Option Fund. All three investors contributed equally. Michael Steinmetz for Clarus